PRESSRELEASES
13 October, 2021
Nanexa signs additional evaluation agreement
Nanexa AB today announced that the company has signed an additional so-called Material Transfer and Feasibility Study Agreement with one of the company’s existing customers, for evaluation of the PharmaShell® technology with a specific biological drug substance.
5 October, 2021
Nanexa receives decision on sanction fee from Finansinspektionen regarding case from 2017
Nanexa AB today announces that the company has received a decision from Finansinspektionen (Sweden’s financial supervisory authority) to pay a penalty fee of SEK 1,000,000 regarding events that occurred in 2017.
CURRENT
28 juni, 2021
Redeye analytiker-intervju med vd David Westberg
17 juni, 2021
Webcast och frågestund
NEWSLETTER
